Last reviewed · How we verify

NCT05936346

Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient

Recruiting now NA Last updated 23 January 2025
What this trial tests

NA trial testing Salvia haenkei 175mg in Aging in 50 participants. Currently enrolling.

Timeline
17 July 2023
Primary endpoint
30 April 2025
30 April 2025

Quick facts

Lead sponsorIBSA Farmaceutici Italia Srl
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment50
Start date17 July 2023
Primary completion30 April 2025
Estimated completion30 April 2025
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

IBSA Farmaceutici Italia Srl

Who can join

Adults 55 to 65, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Other IBSA Farmaceutici Italia Srl trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05936346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing